Email this article 
Hide
Show all
Open Access
Subscription or Fee Access
Systemic sclerosis (Scleroderma) Among Adults Attending the Rheumatology Clinic of a Tertiary Institution
Abstract
Background: Systemic sclerosis is a multi-systemic autoimmune disorder characterised by the generation of autoantibodies, massive deposition of collagen and other matrix substances in the connective tissues and alterations of the microvasculature.
Methods: This was a prospective study of all the cases of scleroderma seen between January 2012 and June 2015 at the Rheumatology Clinic of the Olabisi Onabanjo University Teaching Hospital. All the patients with the diagnosis of scleroderma were included. Excluded from the study were patients with other skin lesions not typical of scleroderma.
Results: Six hundred and six patients with rheumatologic disorders were seen over the study period but eight of them had scleroderma. All the eight cases of scleroderma were females. The age range was 36-52 years with a mean age of 45 years (SD ± 11.4 years). All the cases had arthritis and diffuse skin lesions. Other features included sclerodactyly, microstomia and salt and pepper skin appearance in all the eight cases while Raynaud’s phenomenon and leg ulcers were not frequent. Inflammatory marker (erythrocyte sedimentation rate) was significantly elevated in all the cases. Renal and cardiovascular complications were the leading causes of death.
Conclusion: Diffuse systemic sclerosis is a more serious disease than the limited form. Early referral of patients with skin lesions suggestive of scleroderma to a specialist centre is recommended as symptomatic treatment helps to improve the quality of life.
Keywords
References
Medsger TA Jr. Classification, prognosis. In: Clements PJ, Furst DE (Eds). Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:17–28.
Clements PJ, Medsger TA Jr, Feghali CA. Cutaneous involvement in systemic sclerosis. In: Clements PJ, Furst DE (Eds). Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:129–150.
Korn JH. Pathogenesis of systemic sclerosis. In: Koopman WJ, Moreland LW (Eds). Arthritis and allied conditions. Philadelphia: Lippincott Williams & Wilkins; 2005:1621–1632.
Oguntona SA, Adelowo OO. Raynaud’s phenomenon in a Black African Woman. Niger Hosp Pract 2008; 2: 7-9.
White B. Systemic sclerosis. In: Klippel JH (Editor). Primer on the rheumatic diseases. 12th Edition. Atlanta: Arthritis Foundation; 2001: 353–356.
Korn JH. Pathogenesis of systemic sclerosis. In: Koopman WJ, Moreland LW (Eds). Arthritis and allied conditions. Philadelphia: Lippincott Williams & Wilkins; 2005: 1621–
Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437–2444.
Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wingley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized controlled trial. Ann Intern Med 2000; 132: 425–434.
Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006; 8:151–157.
Adelowo OO, Oguntona SA. Scleroderma (Systemic sclerosis) among Nigerians. Clin Rheumatol 2009; 28: 1121-1125.
Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223-235.
Laing TJ, Gillepsie BW, Toth MB, Mayes MD, Gallavan RH, Burns CJ et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997; 4: 734-742.
Golden JG, Lynch DA, Strollo DC, Suh RD, Schraufnagel DE, Perry M et al. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease. Chest 2008; 134: 358-367.
Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2006; 33: 269–274.
Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792–3800.
Teixera L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110 -116.
Steen VD. Renal involvement in systemic sclerosis. In: Clements PJ, Furst DE (Eds). Systemic sclerosis. Philadelphia: Lippinc Williams & Wilkins; 2004: 279–292.
Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984; 76: 779-786.
Follansbee WP, Marroquin OC. Cardiac involvement in systemic sclerosis. In: Clements PJ, Furst DE (Eds). Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:195–220.
Smith JW, Clements PJ, Levisman J, Furst D, Ross M. Echocardiographic features of progressive systemic sclerosis (PSS): correlation with hemodynamic and postmortem studies. Am J Med 1979; 66: 28–33.
de Groote P, Gressin V, Hachulla E, Carpentier P, Guillevin L, Kahan A, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67:31-36.
Weinstein WM, Kadell BM. The gastrointestinal tract in systemic sclerosis. In: Clements PJ, Furst DE (Eds). Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:293–308.
Lee P, Bruni J, Sukenik S. Neurological manifestations in systemic sclerosis (scleroderma). J Rheumatol 1984; 11: 480-483.
Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004; 16: 723–732.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Annals of Health Research
A publication of the Medical and Dental Consultants Association of Nigeria, Olabisi Onabanjo University Teaching Hospital, (OOUTH) Sagamu Branch, Nigeria